2012
High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers
Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, Broekmans F, Baker VL. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertility And Sterility 2012, 98: 1037-1042. PMID: 22771028, DOI: 10.1016/j.fertnstert.2012.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnti-Mullerian HormoneChemistry, ClinicalEstradiolFemaleFertilityFollicle Stimulating Hormone, HumanHumansMenstrual CycleMiddle AgedOocytesOvulation InductionPredictive Value of TestsPrognosisReference StandardsReproductive MedicineRetrospective StudiesUnited StatesYoung AdultConceptsYears of ageFSH valuesSerum AMHAntimüllerian hormoneAMH valuesFertility centerCut pointsDay 2Clinical discordanceMenstrual cycle day 2Follicle-stimulating hormone levelsCycle day 2Reference laboratoryFollicle-stimulating hormoneLarger patient populationSingle reference laboratoryFrequency of discordanceAge-dependent fashionClinical cut pointsSame serum samplesOvarian stimulationPatient populationAMH testingMenstrual cycleHormone levels
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2003
Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women
Seifer DB, Lambert-Messerlian G, Schneyer AL. Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women. Fertility And Sterility 2003, 79: 451-452. PMID: 12568867, DOI: 10.1016/s0015-0282(02)04669-1.Peer-Reviewed Original Research
2000
Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values?
Trout S, Seifer D. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertility And Sterility 2000, 74: 335-337. PMID: 10927054, DOI: 10.1016/s0015-0282(00)00625-7.Peer-Reviewed Original ResearchConceptsDay 3 serum FSHRecurrent pregnancy lossUnexplained recurrent pregnancy lossCauses of RPLSerum FSHPregnancy lossControl groupOvarian reserveDay 3 FSHUnexplained habitual abortionDiminished ovarian reservePresence of infertilityHistory of infertilityRetrospective comparative analysisUnexplained groupRPL groupHabitual abortionMean ageMAIN OUTCOMEFSHGreater incidenceTest groupWomenPotential roleInfertility
1999
Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone
Seifer D, Scott R, Bergh P, Abrogast L, Friedman C, Mack C, Danforth D. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertility And Sterility 1999, 72: 63-65. PMID: 10428149, DOI: 10.1016/s0015-0282(99)00193-4.Peer-Reviewed Original ResearchConceptsSerum inhibin B levelsInhibin B levelsDay 3 FSH levelsCycle cancellation rateClinical pregnancy rateSerum inhibin BOvarian reserveFSH levelsB levelsInhibin BPregnancy rateCancellation rateDay 3 follicle-stimulating hormoneDay 3 serum FSH levelsHigher cycle cancellation rateTertiary-care fertility centreNumber of ampulesSerum FSH levelsSerum FSH concentrationsFollicle-stimulating hormoneCase-control studyNumber of oocytesOvarian responsivenessFSH concentrationsGonadotropin requirements
1998
Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes
Whitacre K, Seifer D, Friedman C, Coskun S, Kennard E, Kim M, Alak B. Effects of ovarian source, patient age, and menstrual cycle phase on in vitro maturation of immature human oocytes. Fertility And Sterility 1998, 70: 1015-1021. PMID: 9848288, DOI: 10.1016/s0015-0282(98)00339-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingCell CycleCell NucleusCells, CulturedCellular SenescenceFemaleFertilization in VitroHumansMenstrual CycleOocytesOvaryConceptsGerminal vesicle breakdownOvarian sourceNuclear maturationPatient ageGynecologic surgeryFollicular phaseLuteal phaseImmature human oocytesFinal meiotic maturationMenstrual cycle phaseYears of agePercentage of oocytesCycle phaseMetaphase II stageIVF programMenstrual cyclePatient criteriaMAIN OUTCOMEVitro maturationPatientsHuman oocytesOocyte maturationMII stageOocyte's abilityVesicle breakdown